Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

Shelley Wood

December 23, 2020

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

News Daily News

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

Shelley Wood

September 30, 2020

News Conference News ESC 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

Caitlin E. Cox

August 31, 2020

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

Todd Neale

August 30, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Daily News

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

L.A. McKeown

June 08, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Daily News ACC 2020

Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT

Shelley Wood

March 17, 2020

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Caitlin E. Cox

February 07, 2020

News Daily News

Most Clinical Trial Sponsors Fail to Report Data as Mandated by FDA

Michael O'Riordan

January 21, 2020

CME

Advertisement

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Most Clinical Trial Sponsors Fail to Report Data as Mandated by FDA

Aspirin for the Interventionalist: More Than Meets the Eye

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content